RESULTS	The risk of all-cause mortality ( 11.1 % versus 19.3 % ; P = 0.13 ) , aorta-specific mortality ( 6.9 % versus 19.3 % ; P = 0.04 ) , and progression ( 27.0 % versus 46.1 % ; P = 0.04 ) after 5 years was lower with TEVAR than with optimal medical treatment alone .\